HER2 inhibition: from discovery to clinical practice
- PMID: 17200331
- DOI: 10.1158/1078-0432.CCR-06-2405
HER2 inhibition: from discovery to clinical practice
Comment on
-
Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen.Clin Cancer Res. 2007 Jan 1;13(1):228-33. doi: 10.1158/1078-0432.CCR-06-1345. Clin Cancer Res. 2007. PMID: 17200359 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
